Breast Cancer News and Research RSS Feed - Breast Cancer News and Research Twitter

Breast cancer is cancer that forms in tissues of the breast, usually the ducts (tubes that carry milk to the nipple) and lobules (glands that make milk). It occurs in both men and women, although male breast cancer is rare. When breast cancer cells spread to other parts of the body, they are called metastases. There are different kinds of breast cancer. The kind of breast cancer depends on which cells in the breast turn into cancer. Breast cancer can begin in different parts of the breast, like the ducts or the lobes.
Thomas Jefferson University, Exosome Sciences team up to evaluate new liquid biopsy platform

Thomas Jefferson University, Exosome Sciences team up to evaluate new liquid biopsy platform

Today, Thomas Jefferson University announces a partnership with Exosome Sciences Inc. to evaluate a novel liquid biopsy platform that might offer clinicians new and actionable information about a patient's cancer as the disease progresses and changes, via a simple blood test. [More]
Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma Inc. and Medivation, Inc. today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer. [More]
Hitachi Aloka Medical becomes exclusive global distributor of iVu Imaging’s SOFIA system

Hitachi Aloka Medical becomes exclusive global distributor of iVu Imaging’s SOFIA system

Hitachi Aloka Medical, Ltd. (Headquartered in Tokyo, Japan, President: Mr. Minoru Yoshizumi) and iVu Imaging Corporation announced the signing of an agreement making Hitachi Aloka Medical, Ltd. the exclusive global distributor of iVu’s SOFIA system, an automated whole breast ultrasound scanner designed to enable the earlier detection of breast cancer in women with mammographically dense breasts. [More]
Detecting bladder cancer from urine: an interview with Suzana Nahum-Zilberberg, CEO, BioLight

Detecting bladder cancer from urine: an interview with Suzana Nahum-Zilberberg, CEO, BioLight

Bladder cancer is the seventh leading cancer affecting men worldwide and in the United States, it is the fourth leading cancer. Each year, about 350,000 cases are being detected worldwide, and the disease claims 165,000 lives every year. [More]
Breast ultrasound examination may eliminate need for biopsy in teens with breast lumps

Breast ultrasound examination may eliminate need for biopsy in teens with breast lumps

If a lump is found in the breast of an adolescent girl, she often will undergo an excisional biopsy. However, breast cancer is rare in adolescents, and the vast majority of teenage breast lumps turn out to be benign masses that are related to hormones and often go away over time. [More]
Investigational S-equol nutritional supplement may alleviate certain menopause symptoms

Investigational S-equol nutritional supplement may alleviate certain menopause symptoms

The investigational S-equol nutritional supplement may be a viable agent to alleviate certain menopause symptoms, such as hot flashes, according to a new peer-reviewed article in the March Journal of Women's Health. [More]
CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that the China Food and Drug Administration (CFDA) has approved the Company's application to conduct a Phase 2 global clinical trial in ovarian clear cell carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076. [More]
Australian researchers find gene that drives aggressive form of triple-negative breast cancer

Australian researchers find gene that drives aggressive form of triple-negative breast cancer

Australian researchers have found that so-called 'triple-negative breast cancers' are two distinct diseases that likely originate from different cell types. This helps explain why survival prospects for women with the diagnosis tend to be either very good or very bad. [More]
Stopping cellular quality-control mechanism can make chemotherapy more effective

Stopping cellular quality-control mechanism can make chemotherapy more effective

A University of Rochester team found a way to make chemotherapy more effective, by stopping a cellular quality-control mechanism, according to a study published today in Nature Communications. [More]
Taconic, Cellaria partner to facilitate use of patient-derived xenografts for oncology research

Taconic, Cellaria partner to facilitate use of patient-derived xenografts for oncology research

Taconic Biosciences and Cellaria Biosciences today announced that the two companies have entered into a scientific collaboration designed to facilitate and improve the utility of patient-derived xenografts (PDXs) in animal models for oncology and immuno-oncology research. Cellaria’s novel methodologies for generating cells from patient tumors will complement Taconic’s industry-leading portfolio of tissue humanized mouse models, which are well-suited as hosts for PDXs. [More]
CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, China. [More]
Scientists establish scientific basis for scalp cooling that can ensure hair retention after cancer treatment

Scientists establish scientific basis for scalp cooling that can ensure hair retention after cancer treatment

HAIR loss is one of the most distressing side-effects of cancer treatment and can even deter some patients from undergoing life-saving chemotherapy. But researchers at the University of Huddersfield are establishing the scientific basis for a rapidly-advancing scalp cooling technology that can ensure hair retention in a vast number of cases. [More]
Immunomagnetic assay with microfluidic technology can capture, manipulate circulating tumor cells

Immunomagnetic assay with microfluidic technology can capture, manipulate circulating tumor cells

To quantify rare tumor markers that will allow oncologists to make prognoses and select therapies, John X.J. Zhang, PhD led a team of bioengineers from the Thayer School of Engineering at Dartmouth in demonstrating a novel system that couples nano-engineered particles and microfluidic chips for capturing and manipulating circulating tumor cells (CTCs). [More]
Study confirms strong association between diabetes and later stage breast cancer

Study confirms strong association between diabetes and later stage breast cancer

Diabetes is associated with more advanced stage breast cancer, according to a new study by the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital. [More]
TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

Teikoku Pharma USA announced today that it has submitted a 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration for Docetaxel Injection Concentrate, Non-Alcohol Formula on February 26, 2015 and received an acknowledgment of the receipt from FDA. [More]
New report highlights the need for disclosing Alzheimer's diagnosis to patients

New report highlights the need for disclosing Alzheimer's diagnosis to patients

The Alzheimer's Association's 2015 Alzheimer's Disease Facts and Figures report, released today, found that only 45 percent of people with Alzheimer's disease or their caregivers say they were told the diagnosis by their doctor. [More]
Researchers and medical bodies explore ways to secure funds for womb cancer research

Researchers and medical bodies explore ways to secure funds for womb cancer research

A national group of researchers, medical bodies and charities, led by The University of Manchester is looking for help in setting the top priorities for fighting womb cancer, with a survey launched today (23 March 2015). [More]
Existing drugs could help prevent deadly familial stomach and lobular breast cancers

Existing drugs could help prevent deadly familial stomach and lobular breast cancers

Deadly familial stomach and lobular breast cancers could be successfully treated at their earliest stages, or even prevented, by existing drugs that have been newly identified by cancer genetics researchers at New Zealand's University of Otago. [More]
Genomic Health presents 11 studies demonstrating value of Oncotype DX breast cancer test

Genomic Health presents 11 studies demonstrating value of Oncotype DX breast cancer test

Genomic Health today announced the presentation of 11 studies with the Oncotype DX breast cancer test at the 14th St. Gallen Breast Cancer Conference in Vienna, Austria. Studies presented include results from a real-life observational study in Ireland demonstrating significant reductions in chemotherapy and resulting cost savings when the test is used in early stage breast cancer. [More]
Women diagnosed with DCIS or atypia should seek second opinions, says study

Women diagnosed with DCIS or atypia should seek second opinions, says study

While doctors almost always agree on a pathological diagnosis of invasive breast cancer, there is room for improvement when diagnosing atypia (or atypical ductal hyperplasia-ADH) and DCIS (ductal carcinoma in-situ), Anna Tosteson, ScD and Tracy Onega, PhD from Dartmouth-Hitchcock's Norris Cotton Cancer Center have found. [More]
Advertisement
Advertisement